Phase I clinical trial testing the dose escalation and expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin administration (PITHAC) for the management of pleural carcinosis
Cancer Treatment and Research Communications · 2024
DOI: 10.1016/j.ctarc.2024.100858 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Treatment and Research Communications, 2024. Verfasst von Louis-Emmanuel Chriqui und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, University Hospital of Lausanne, Rue du Bugnon 46 1011, Lausanne, Switzerland. Hauptthemen laut MEDLINE: Cisplatin, Hyperthermia, Induced, Pleural Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ISREC Foundation.
Abstract (Originalsprache)
BACKGROUND: Pleural carcinosis originates from various cancers. Its management consists in systemic therapies combined to dyspnea relief procedures. Prior studies have tested hyperthermic intrathoracic chemotherapy to treat pleural carcinosis with interesting patient survival results. However, these approaches were limited by local toxicity. Pre-clinical data have shown that hyperthermia combined to local pleural chemotherapy increased the immune response against tumors. Recently, pressurized intraperitoneal aerosol chemotherapies (PIPAC) showed improved cytostatic penetration in abdominal carcinosis with a 10-fold-lower chemotherapy dose and minimal side-effects. This approach was also tested in limited numbers of patients with pleural carcinosis but never combined with hyperthermia. METHODS: Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin (PITHAC) is an open-label dose-escalation phase I trial. Patients with pleural carcinosis, eligible for the surgical management of their pleural effusion can be enrolled. Cisplatin (7.5-12-5-35-70 mg/m2) heated at 39±1 °C is delivered into the thoracic cavity before the surgical effusion management. Initially, the study consists in a dose escalation of the four different cisplatin doses. The primary endpoint is the maximal tolerated dose of cisplatin administered by PITHAC. The secondary and translational endpoints are adverse events and the immune response directed against cancer following PITHAC. There is then an expansion phase at the recommended cisplatin dose on an additional 15 patients with identical outcomes. DISCUSSION: Pressurized intrathoracic delivery of chemotherapy under hyperthermic conditions was never tested so far. We plan to determine the safety of such an approach in patients managed for pleural carcinosis. If proven safe, PITHAC could be combined with systemic immunotherapies for the management of cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06281860.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thoracic Surgery, University Hospital of Lausanne, Rue du Bugnon 46 1011, Lausanne, Switzerland.
- Sponsor Research Office (SRO, University Hospital of Lausanne, Rue du Bugnon 46 1011, Lausanne, Switzerland.
- Division of Visceral Surgery, University Hospital of Lausanne, Rue du Bugnon 46 1011, Lausanne, Switzerland.
- Division of Oncology, University Hospital of Lausanne, Rue du Bugnon 46 1011, Lausanne, Switzerland.
- Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland; Center for Cell…
- Division of Thoracic Surgery, University Hospital of Lausanne, Rue du Bugnon 46 1011, Lausanne, Switzerland. Electronic address: jean.perentes@chuv.ch.
Förderung
- ISREC Foundation
Zitieren
APA
Chriqui, L. E., Abdelnour-Berchtold, E., Zanfrini, E., Devesa-Perez, S., Gonzalez, M., Krueger, T., Ellefsen, K., Destaillats, A., Bonnet, D., Hübner, M., Bouchaab, H., Bassani-Sternberg, M., Peters, S., Cavin, S., & Perentes, J. Y. (2024). Phase I clinical trial testing the dose escalation and expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin administration (PITHAC) for the management of pleural carcinosis. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2024.100858
Vancouver
Chriqui LE, Abdelnour-Berchtold E, Zanfrini E, Devesa-Perez S, Gonzalez M, Krueger T, et al. Phase I clinical trial testing the dose escalation and expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin administration (PITHAC) for the management of pleural carcinosis. Cancer Treatment and Research Communications. 2024. doi:10.1016/j.ctarc.2024.100858
BibTeX
@article{Chriqui2024,
author = {Chriqui, Louis-Emmanuel and Abdelnour-Berchtold, Etienne and Zanfrini, Edoardo and Devesa-Perez, Severine and Gonzalez, Michel and Krueger, Thorsten and Ellefsen, Kim and Destaillats, Alice and Bonnet, David and Hübner, Martin and Bouchaab, Hasna and Bassani-Sternberg, Michal and Peters, Solange and Cavin, Sabrina and Perentes, Jean Y},
title = {Phase I clinical trial testing the dose escalation and expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin administration (PITHAC) for the management of pleural carcinosis},
journal = {Cancer Treatment and Research Communications},
year = {2024},
doi = {10.1016/j.ctarc.2024.100858}
}
EUVIMED